Abstract 58P
Background
Myelodysplastic syndromes (MDS) are a group of blood cancers which are characterized by ineffective hematopoiesis of bone marrow cells and abnormal blood cell development leading to cytopenias and an increased risk for progression to acute myeloid leukemia. At diagnosis, 50% of MDS patients have a normal conventional karyotype, however, unbalanced chromosomal aberrations are common and have prognostic implications. We aimed to investigate the unbalanced chromosomal aberrations in MDS patients with normal bone marrow karyotype using micro-array-based Comparative Genomic Hybridization (aCGH).
Methods
aCGH was performed on peripheral blood extracted DNA from 5 patients with clinical MDS features and normal bone marrow karyotype and we employed a Multiplex Ligation-dependent Probe Amplification (MLPA®) analysis to confirm the Subtelomeric copy number variations (CNVs).
Results
The aCGH analysis (NCBI36/hg18) revealed copy-number variations (CNV) in all patients with normal karyotype. All the 5 patients carried 16 copy-number variations (CNV), including 8 duplications ranging from 20 killobases (Kb) to 2,283 megabases (Mb), they include chromosomal regions 1q44; 2p16; 5q12, 10q27;14q12; 22q11; Xq21.3; Xq27.3 and 8 deletions ranging from 26.3 Kb to 948.9 kb, including chromosomal regions 1p36.1; 1q21; 4q31; 5p15.4; 9q21.1; 10q24; 22q21. Subtelomeric CNV (5p15; 10q27 and 1q44) were approved by using Multiplex Ligation-dependent Probe Amplification (MLPA®) analysis with SALSA MLPA Probemix P036 Subtelomeres Mix 1.
Conclusions
These results demonstrated that chromosomal defects in MDS may be more frequent than predicted by metaphase cytogenetics and new cryptic lesions may be revealed by precise analysis methods. This study suggests a significant role for the use of aCGH in the clinical workup of MDS patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract